Xenon Pharmaceuticals (XENE) Projected to Post Earnings on Monday

Xenon Pharmaceuticals (NASDAQ:XENE) is expected to post its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to announce earnings of ($1.13) per share and revenue of $1.33 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.05. During the same quarter last year, the business posted ($1.07) earnings per share. On average, analysts expect Xenon Pharmaceuticals to post ($4.66) EPS for the current fiscal year and ($4.83) EPS for the next fiscal year.

Xenon Pharmaceuticals Stock Performance

XENE stock opened at $37.41 on Friday. The company has a 50 day moving average price of $45.35 and a 200 day moving average price of $52.21. Xenon Pharmaceuticals has a fifty-two week low of $33.38 and a fifty-two week high of $72.66.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, Director Steven Gannon sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total value of $640,600.00. Following the completion of the transaction, the director directly owned 1,870 shares of the company’s stock, valued at approximately $119,792.20. The trade was a 84.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Thomas Patrick Kelly purchased 15,000 shares of the stock in a transaction on Wednesday, September 30th. The stock was acquired at an average price of $37.32 per share, with a total value of $559,800.00. Following the completion of the acquisition, the chief financial officer directly owned 15,000 shares of the company’s stock, valued at approximately $559,800. This represents a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 2.91% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

XENE has been the subject of several research reports. Jefferies Financial Group reissued a “buy” rating and issued a $90.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, September 28th. HC Wainwright restated a “buy” rating on shares of Xenon Pharmaceuticals in a research report on Friday, September 18th. Wall Street Zen cut Xenon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Sunday, October 11th. Wedbush decreased their price target on Xenon Pharmaceuticals from $71.00 to $55.00 and set an “outperform” rating on the stock in a report on Friday, September 18th. Finally, Deutsche Bank Aktiengesellschaft lowered Xenon Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $90.00 to $46.00 in a research report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $70.14.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for neurological and psychiatric disorders. The company uses expertise in human genetics and ion-channel biology to identify potential treatments for diseases with significant unmet medical needs, particularly epilepsy and other disorders of the nervous system.

Xenon’s lead investigational product is azetukalner, also known as XEN1101, a selective potassium-channel opener being evaluated for epilepsy and other potential neurological and psychiatric applications.